Evan Y. Yu, MD

Articles

Dr. Yu on Future Directions in Prostate Cancer

July 25th 2019

Evan Y. Yu, MD, professor, Department of Medical Oncology, University of Washington School of Medicine, member, Clinical Research Division, Fred Hutchinson Cancer Research Center, and clinical trials core director, Genitourinary Medical Oncology, Seattle Cancer Care Alliance, discusses future directions in prostate cancer.

Dr. Yu on Initial Findings From the KEYNOTE-365 Trial in mCRPC

July 19th 2019

Evan Y. Yu, MD, professor, Department of Medical Oncology, University of Washington School of Medicine, member, Clinical Research Division, Fred Hutchinson Cancer Research Center, and clinical trials core director, Genitourinary Medical Oncology, Seattle Cancer Care Alliance, discusses initial findings from the KEYNOTE-365 trial in metastatic castration resistant prostate cancer mCRPC).

Dr. Yu on Rationale for the KEYNOTE-365 Study in mCRPC

July 9th 2019

Evan Y. Yu, MD, discusses the rationale behind the KEYNOTE-365 trial, looking at pembrolizumab plus olaparib in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel.

Dr. Yu on Combining Pembrolizumab and Olaparib in mCRPC

June 21st 2019

Evan Y. Yu, MD, professor, Department of Medicine, Division of Oncology, University of Washington, Seattle Cancer Care Alliance, discusses combining pembrolizumab and olaparib in metastatic castration-resistant prostate cancer.

Dr. Yu Discusses Treatment Strategies for Patients With Oligometastatic Prostate Cancer

February 23rd 2019

Evan Y. Yu, MD, professor, Department of Medicine, Division of Oncology, University of Washington, Seattle Cancer Care Alliance, discusses treatment strategies for patients with oligometastatic prostate cancer.

Dr. Yu on Combination Therapy for Patients With Metastatic Prostate Cancer

February 14th 2019

Evan Y. Yu, MD, professor, Department of Medicine, Division of Oncology, University of Washington, Seattle Cancer Care Alliance, discusses combination therapy for patients with newly diagnosed metastatic prostate cancer.

Dr. Yu on the Future of Castration-Sensitive Prostate Cancer

August 2nd 2018

Evan Y. Yu, MD, professor, Department of Medicine, Division of Oncology, University of Washington, Seattle Cancer Care Alliance, discusses the future of castration-sensitive prostate cancer.

Dr. Yu on Treatment Intensification in Metastatic Castration-Sensitive Prostate Cancer

June 25th 2018

Evan Y. Yu, MD, professor, Department of Medicine, Division of Oncology, University of Washington, Seattle Cancer Care Alliance, discusses treatment intensification in patients with metastatic castration-sensitive prostate cancer.

Dr. Yu on Comorbidities and Therapy Choice in Prostate Cancer

June 6th 2018

Evan Y. Yu, MD, professor, Department of Medicine, Division of Oncology, University of Washington, Seattle Cancer Care Alliance, discusses how comorbidities factor into treatment choice for patients with castration-sensitive prostate cancer.

Dr. Yu on the Association of ALP With Outcomes in Patients With mCRPC

May 1st 2014

Evan Y. Yu, MD, from Seattle Cancer Care Alliance, discusses the association of alkaline phosphatase with outcomes in chemotherapy-naive patients with metastatic castration-resistant prostate cancer.

Dr. Yu Discusses the Utility of GTx-758 in mCRPC

February 24th 2014

Evan Y. Yu, MD, associate professor, Department of Medicine, Division of Oncology, University of Washington School of Medicine, Seattle Cancer Care Alliance, discusses the utility of GTx-758 in mCRPC.

Dr. Yu Discusses Optimal Testosterone Suppression

February 6th 2014

Evan Y. Yu, MD, associate professor, Department of Medicine, Division of Oncology, University of Washington School of Medicine, Seattle Cancer Care Alliance, discusses an analysis of optimal testosterone suppression on medical ADT.

Dr. Yu on the Role of PET Imaging in Prostate Cancer

November 14th 2013

Evan Y. Yu, MD, associate professor, Department of Medicine, Division of Oncology, Seattle Cancer Care Alliance, discusses the role of PET imaging in prostate cancer.